Issue 41, 2018

Photoactivation of imatinib–antibody conjugate using low-energy visible light from Ru(ii)-polypyridyl cages

Abstract

Ru(II)-polypyridyl cages with sterically bulky bidentate ligands provide efficient photochemical release of the anticancer drug imatinib using low energy visible light, imparting spatiotemporal control over drug bioavailability. The light-activated drug release is maintained when the Ru(II) cage is covalently coupled to an antibody, which is expected to localize selectively on the tumor.

Graphical abstract: Photoactivation of imatinib–antibody conjugate using low-energy visible light from Ru(ii)-polypyridyl cages

Supplementary files

Article information

Article type
Communication
Submitted
15 Feb 2018
Accepted
23 Apr 2018
First published
30 Apr 2018

Chem. Commun., 2018,54, 5193-5196

Author version available

Photoactivation of imatinib–antibody conjugate using low-energy visible light from Ru(II)-polypyridyl cages

T. N. Rohrabaugh, A. M. Rohrabaugh, J. J. Kodanko, J. K. White and C. Turro, Chem. Commun., 2018, 54, 5193 DOI: 10.1039/C8CC01348A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements